# Sven Perner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2609786/publications.pdf

Version: 2024-02-01

| 150 | 21,338 | 25034 57 | 9589 142 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 152 | 152 | 152 | 26775 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer. Science, 2005, 310, 644-648. | 12.6 | 3,541 |
| 2 | Comprehensive genomic profiles of small cell lung cancer. Nature, 2015, 524, 47-53. | 27.8 | 1,634 |
| 3 | Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics, 2012, 44, 1104-1110. | 21.4 | 1,186 |
| 4 | Characterizing the cancer genome in lung adenocarcinoma. Nature, 2007, 450, 893-898. | 27.8 | 1,020 |
| 5 | Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20007-20012. | 7.1 | 927 |
| 6 | SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nature Genetics, 2009, 41, 1238-1242. | 21.4 | 862 |
| 7 | Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer. Science Translational Medicine, 2010, 2, 62ra93. | 12.4 | 761 |
| 8 | Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. Cancer Discovery, 2011, 1, 487-495. | 9.4 | 725 |
| 9 | Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature, 2015, 526, 700-704. | 27.8 | 478 |
| 10 | TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer. Cancer Research, 2006, 66, 8337-8341. | 0.9 | 475 |
| 11 | TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion. American Journal of Surgical Pathology, 2007, 31, 882-888. | 3.7 | 394 |
| 12 | Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Human Pathology, 2007, 38, 696-701. | 2.0 | 388 |
| 13 | Prevention and early detection of prostate cancer. Lancet Oncology, The, 2014, 15, e484-e492. | 10.7 | 372 |
| 14 | Gleason Score and Lethal Prostate Cancer: Does 3 + 4 = 4 + 3?. Journal of Clinical Oncology, 2009, 27, 3459-3464. | 1.6 | 329 |
| 15 | The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers. Cancer Cell, 2008, 13, 519-528. | 16.8 | 303 |
| 16 | Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer. Journal of the National Cancer Institute, 2008, 100, 815-825. | 6.3 | 286 |
| 17 | Rationale for co-targeting IGF-1R and ALK in ALK fusionâ€“positive lung cancer. Nature Medicine, 2014, 20, 1027-1034. | 30.7 | 243 |
| 18 | CD74â€“NRG1 Fusions in Lung Adenocarcinoma. Cancer Discovery, 2014, 4, 415-422. | 9.4 | 238 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | EML4-ALK Fusion Lung Cancer: A Rare Acquired Event. Neoplasia, 2008, 10, 298-302. | 5.3 | 231 |
| 20 | A mechanistic classification of clinical phenotypes in neuroblastoma. Science, 2018, 362, 1165-1170. | 12.6 | 213 |
| 21 | Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States. Clinical Cancer Research, 2009, 15, 4706-4711. | 7.0 | 205 |
| 22 | Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer. Neoplasia, 2013, 15, 1-IN4. | 5.3 | 205 |
| 23 | Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications. Clinical Cancer Research, 2008, 14, 3380-3385. | 7.0 | 200 |
| 24 | Imaging prostate cancer with 11C-choline PET/CT. Journal of Nuclear Medicine, 2006, 47, 1249-54. | 5.0 | 191 |
| 25 | SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Modern Pathology, 2011, 24, 944-953. | 5.5 | 177 |
| 26 | TMPRSS2-ERG Fusion Heterogeneity in Multifocal Prostate Cancer: Clinical and Biologic Implications. Urology, 2007, 70, 630-633. | 1.0 | 146 |
| 27 | <scp>NOTCH</scp>, <scp>ASCL1</scp>, p53 and <scp>RB</scp> alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. International Journal of Cancer, 2016, 138, 927-938. | 5.1 | 143 |
| 28 | Prevalence of TMPRSS2â€“ERG and SLC45A3â€“ERG gene fusions in a large prostatectomy cohort. Modern Pathology, 2010, 23, 539-546. | 5.5 | 141 |
| 29 | FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies. Clinical Cancer Research, 2014, 20, 3299-3309. | 7.0 | 141 |
| 30 | mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 2391-2396. | 1.6 | 140 |
| 31 | Web-TCGA: an online platform for integrated analysis of molecular cancer data sets. BMC Bioinformatics, 2016, 17, 72. | 2.6 | 140 |
| 32 | Human prostate sphereâ€forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate, 2010, 70, 491-501. | 2.3 | 130 |
| 33 | SOX2 Expression Associates with Stem Cell State in Human Ovarian Carcinoma. Cancer Research, 2013, 73, 5544-5555. | 0.9 | 129 |
| 34 | Molecular Characterization of TMPRSS2-ERG Gene Fusion in the NCI-H660 Prostate Cancer Cell Line: A New Perspective for an Old Model. Neoplasia, 2007, 9, 200-IN3. | 5.3 | 119 |
| 35 | Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Modern Pathology, 2012, 25, 1473-1480. | 5.5 | 118 |
| 36 | ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Modern Pathology, 2010, 23, 1061-1067. | 5.5 | 114 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis. Frontiers in Oncology, 2018, 8, 623. | 2.8 | 108 |
| 38 | An Oncogenic Role for ETV1 in Melanoma. Cancer Research, 2010, 70, 2075-2084. | 0.9 | 107 |
| 39 | N-myc Downstream Regulated Gene 1 (NDRG1) Is Fused to ERG in Prostate Cancer. Neoplasia, 2009, 11, 804-W18. | 5.3 | 105 |
| 40 | Clinical significance of TTFâ€1 protein expression and TTFâ€1 gene amplification in lung adenocarcinoma. Journal of Cellular and Molecular Medicine, 2009, 13, 1977-1986. | 3.6 | 98 |
| 41 | PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. OncoImmunology, 2016, 5, e1131379. | 4.6 | 94 |
| 42 | Quantifying Telomere Lengths of Human Individual Chromosome Arms by Centromere-Calibrated Fluorescence in Situ Hybridization and Digital Imaging. American Journal of Pathology, 2003, 163, 1751-1756. | 3.8 | 92 |
| 43 | Novel approaches to target the microenvironment of bone metastasis. Nature Reviews Clinical Oncology, 2021, 18, 488-505. | 27.6 | 91 |
| 44 | Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes and Cancer, 2009, 48, 366-380. | 2.8 | 86 |
| 45 | AIM2 Drives Joint Inflammation in a Self-DNA Triggered Model of Chronic Polyarthritis. PLoS ONE, 2015, 10, e0131702. | 2.5 | 85 |
| 46 | ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma. Cancer Research, 2017, 77, 3040-3056. | 0.9 | 81 |
| 47 | Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biology and Therapy, 2009, 8, 2042-2050. | 3.4 | 78 |
| 48 | FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. Clinical Cancer Research, 2015, 21, 4356-4364. | 7.0 | 75 |
| 49 | Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer. Clinical Cancer Research, 2017, 23, 1829-1840. | 7.0 | 74 |
| 50 | Differences in Frequency of ERG Oncoprotein Expression Between Index Tumors of Caucasian and African American Patients With Prostate Cancer. Urology, 2012, 80, 749-753. | 1.0 | 73 |
| 51 | Assembly of methylated KDM1A and CHD1 drives androgen receptorâ€“dependent transcription and translocation. Nature Structural and Molecular Biology, 2016, 23, 132-139. | 8.2 | 70 |
| 52 | KDM5C Is Overexpressed in Prostate Cancer and Is a Prognostic Marker for Prostate-Specific Antigen-Relapse Following Radical Prostatectomy. American Journal of Pathology, 2014, 184, 2430-2437. | 3.8 | 69 |
| 53 | Expression and role of the embryonic protein SOX2 in head and neck squamous cell carcinoma. Carcinogenesis, 2014, 35, 1636-1642. | 2.8 | 66 |
| 54 | Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. British Journal of Haematology, 2015, 169, 415-422. | 2.5 | 66 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | ERG rearrangement in small cell prostatic and lung cancer. Histopathology, 2010, 56, 937-943. | 2.9 | 64 |
| 56 | Chromothripsis followed by circular recombination drives oncogene amplification in human cancer. Nature Genetics, 2021, 53, 1673-1685. | 21.4 | 61 |
| 57 | Aberrant Cytoplasmic Expression of p63 and Prostate Cancer Mortality. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 595-600. | 2.5 | 60 |
| 58 | Validation of a TFE3 Break-apart FISH Assay for Xp11.2 Translocation Renal Cell Carcinomas. Diagnostic Molecular Pathology, 2011, 20, 129-137. | 2.1 | 60 |
| 59 | Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer. Oncotarget, 2015, 6, 35542-35555. | 1.8 | 60 |
| 60 | DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathologica, 2018, 136, 255-271. | 7.7 | 59 |
| 61 | KMT9 monomethylates histone H4 lysine 12 and controls proliferation of prostate cancer cells. Nature Structural and Molecular Biology, 2019, 26, 361-371. | 8.2 | 57 |
| 62 | ERG Rearrangement Metastasis Patterns in Locally Advanced Prostate Cancer. Urology, 2010, 75, 762-767. | 1.0 | 56 |
| 63 | Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck. Modern Pathology, 2013, 26, 1298-1306. | 5.5 | 54 |
| 64 | Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma. Frontiers in Medicine, 2019, 6, 27. | 2.6 | 54 |
| 65 | Development and Clinical Validation of a Real-Time PCR Assay for PITX2 DNA Methylation to Predict Prostate-Specific Antigen Recurrence in Prostate Cancer Patients Following Radical Prostatectomy. Journal of Molecular Diagnostics, 2013, 15, 270-279. | 2.8 | 53 |
| 66 | The activation of OR51E1 causes growth suppression of human prostate cancer cells. Oncotarget, 2016, 7, 48231-48249. | 1.8 | 53 |
| 67 | GNAS Sequencing Identifies IPMN-specific Mutations in a Subgroup of Diminutive Pancreatic Cysts Referred to as â€œIncipient IPMNsâ€• American Journal of Surgical Pathology, 2014, 38, 360-363. | 3.7 | 52 |
| 68 | Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system. Histology and Histopathology, 2013, 28, 605-10. | 0.7 | 52 |
| 69 | ERG Cooperates with Androgen Receptor in Regulating Trefoil Factor 3 in Prostate Cancer Disease Progression. Neoplasia, 2010, 12, 1031-IN22. | 5.3 | 51 |
| 70 | Low-levelAPCmutational mosaicism is the underlying cause in a substantial fraction of unexplained colorectal adenomatous polyposis cases. Journal of Medical Genetics, 2016, 53, 172-179. | 3.2 | 51 |
| 71 | Disruption of the PRKCDâ€“FBXO25â€“HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis. Nature Medicine, 2014, 20, 1401-1409. | 30.7 | 50 |
| 72 | Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion. Clinical Cancer Research, 2021, 27, 632-644. | 7.0 | 49 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Rationale for Treatment of Metastatic Squamous Cell Carcinoma of the Lung Using Fibroblast Growth Factor Receptor Inhibitors. Chest, 2012, 142, 1020-1026. | 0.8 | 47 |
| 74 | Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer. Modern Pathology, 2015, 28, 138-145. | 5.5 | 45 |
| 75 | A Case of Sudden Cardiac Death Due to Isolated Eosinophilic Coronary Arteritis. Chest, 2005, 128, 1047-1050. | 0.8 | 42 |
| 76 | Survival According to BRAF-V600 Tumor Mutations â€“ An Analysis of 437 Patients with Primary Melanoma. PLoS ONE, 2014, 9, e86194. | 2.5 | 42 |
| 77 | Prognostic factors in lymph node-positive prostate cancer. Urology, 2006, 67, 1016-1021. | 1.0 | 41 |
| 78 | The peripheral zone of the prostate is more prone to tumor development than the transitional zone: Is the ETS family the key?. Molecular Medicine Reports, 2012, 5, 313-6. | 2.4 | 41 |
| 79 | Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma. Histopathology, 2013, 63, 157-166. | 2.9 | 41 |
| 80 | Exome sequencing identifies potential novel candidate genes in patients with unexplained colorectal adenomatous polyposis. Familial Cancer, 2016, 15, 281-288. | 1.9 | 40 |
| 81 | Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3â€ERG gene rearrangement and an unfavorable clinical course. International Journal of Cancer, 2013, 132, 807-812. | 5.1 | 39 |
| 82 | Nonamplified FGFR1 Is a Growth Driver in Malignant Pleural Mesothelioma. Molecular Cancer Research, 2014, 12, 1460-1469. | 3.4 | 38 |
| 83 | Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model. Biochemical Pharmacology, 2009, 78, 1127-1138. | 4.4 | 37 |
| 84 | Sequential resection of malignant ureteral margins at radical cystectomy: a critical assessment of the value of frozen section analysis. World Journal of Urology, 2011, 29, 451-456. | 2.2 | 37 |
| 85 | SOX2 Expression and Prognostic Significance in Ovarian Carcinoma. International Journal of Gynecological Pathology, 2013, 32, 358-367. | 1.4 | 37 |
| 86 | Molecular and functional interactions between AKT and SOX2 in breast carcinoma. Oncotarget, 2015, 6, 43540-43556. | 1.8 | 37 |
| 87 | Prominent Oncogenic Roles of EVI1 in Breast Carcinoma. Cancer Research, 2017, 77, 2148-2160. | 0.9 | 36 |
| 88 | Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression. International Journal of Molecular Sciences, 2017, 18, 7. | 4.1 | 36 |
| 89 | Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer. Histopathology, 2011, 58, 1028-1036. | 2.9 | 33 |
| 90 | Genome-Wide Linkage Analysis of TMPRSS2-ERG Fusion in Familial Prostate Cancer. Cancer Research, 2009, 69, 640-646. | 0.9 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Role of the NK Cell-Activating Receptor CRACC in Periodontitis. Infection and Immunity, 2013, 81, 690-696. | 2.2 | 32 |
| 92 | Sex Determining Region Y-Box 2 (SOX2) Amplification Is an Independent Indicator of Disease Recurrence in Sinonasal Cancer. PLoS ONE, 2013, 8, e59201. | 2.5 | 32 |
| 93 | Identification of novel differentially expressed lncRNA and mRNA transcripts in clear cell renal cell carcinoma by expression profiling. Genomics Data, 2015, 5, 173-175. | 1.3 | 32 |
| 94 | Activation of Invariant NK T Cells in Periodontitis Lesions. Journal of Immunology, 2013, 190, 2282-2291. | 0.8 | 30 |
| 95 | Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. European Urology, 2021, 79, 519-529. | 1.9 | 30 |
| 96 | A fatal case of necrotizing sinusitis due to toxigenic Corynebacterium ulcerans. International Journal of Medical Microbiology, 2002, 292, 59-63. | 3.6 | 29 |
| 97 | Single-Cell Genetic Analysis Reveals Insights into Clonal Development of Prostate Cancers and Indicates Loss of PTEN as a Marker of Poor Prognosis. American Journal of Pathology, 2014, 184, 2671-2686. | 3.8 | 29 |
| 98 | Exome Enrichment and SOLiD Sequencing of Formalin Fixed Paraffin Embedded (FFPE) Prostate Cancer Tissue. International Journal of Molecular Sciences, 2012, 13, 8933-8942. | 4.1 | 28 |
| 99 | Prognostic significance of phospho-histone H3 in prostate carcinoma. World Journal of Urology, 2014, 32, 703-707. | 2.2 | 28 |
| 100 | An illustration of the potential for mapping MRI/MRS parameters with genetic over-expression profiles in human prostate cancer. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2008, 21, 411-421. | 2.0 | 27 |
| 101 | Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib. International Journal of Cancer, 2016, 139, 2359-2369. | 5.1 | 27 |
| 102 | Loss of Mucosal p32/gC1qR/HABP1 Triggers Energy Deficiency and Impairs Goblet Cell Differentiation in Ulcerative Colitis. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 229-250. | 4.5 | 27 |
| 103 | Prognostic significance of venous tumour thrombus consistency in patients with renal cell carcinoma (<scp>RCC</scp>). BJU International, 2014, 113, 209-217. | 2.5 | 26 |
| 104 | Fibroblast Growth Factor Receptor 1 as a Putative Therapy Target in Colorectal Cancer. Digestion, 2013, 88, 172-181. | 2.3 | 25 |
| 105 | A randomized trial (RAREST-01) comparing MepitelÂ® Film and standard care for prevention of radiation dermatitis in patients irradiated for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN). Radiotherapy and Oncology, 2019, 139, 79-82. | 0.6 | 25 |
| 106 | Lung cancer biomarker testing: perspective from Europe. Translational Lung Cancer Research, 2020, 9, 887-897. | 2.8 | 25 |
| 107 | In Situ Evidence of KRAS Amplification and Association With Increased p21 Levels in Nonâ€“Small Cell Lung Carcinoma. American Journal of Clinical Pathology, 2009, 132, 500-505. | 0.7 | 24 |
| 108 | MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castrationâ€resistant prostate cancer. International Journal of Cancer, 2014, 135, 19-26. | 5.1 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types. Oncotarget, 2016, 7, 23043-23055. | 1.8 | 24 |
| 110 | Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer. International Journal of Cancer, 2020, 146, 577-588. | 5.1 | 23 |
| 111 | Expression changes of CAV1 and EZH2, located on 7q31âˆ¼q36, are rarely related to genomic alterations in primary prostate carcinoma. Cancer Genetics and Cytogenetics, 2008, 182, 103-110. | 1.0 | 22 |
| 112 | Comparison of p40 (Î”<scp>N</scp>p63) and p63 expression in prostate tissues â€“ which one is the superior diagnostic marker for basal cells?. Histopathology, 2013, 63, 50-56. | 2.9 | 22 |
| 113 | Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer. Pathology, 2015, 47, 629-636. | 0.6 | 22 |
| 114 | Immunometabolic Determinants of Chemoradiotherapy Response and Survival in Head and Neck Squamous Cell Carcinoma. American Journal of Pathology, 2018, 188, 72-83. | 3.8 | 22 |
| 115 | Clinical and Molecular Implications of MED15 in Head and Neck Squamous Cell Carcinoma. American Journal of Pathology, 2015, 185, 1114-1122. | 3.8 | 21 |
| 116 | Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancer. International Journal of Cancer, 2017, 141, 1643-1653. | 5.1 | 21 |
| 117 | Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups. Frontiers in Medicine, 2017, 4, 157. | 2.6 | 21 |
| 118 | Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 561-568. | 2.8 | 21 |
| 119 | MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. Oncotarget, 2017, 8, 14719-14735. | 1.8 | 21 |
| 120 | Testing a Multigene Signature of Prostate Cancer Death in the Swedish Watchful Waiting Cohort. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1682-1688. | 2.5 | 19 |
| 121 | Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a Tp53 Context-Specific Manner. Molecular Cancer Research, 2016, 14, 1110-1123. | 3.4 | 18 |
| 122 | TRIM24 as an independent prognostic biomarker for prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 576.e1-576.e10. | 1.6 | 18 |
| 123 | Differential and Mutually Exclusive Expression of CD95 and CD95 Ligand in Epithelia of Normal Pancreas and Chronic Pancreatitis. Laboratory Investigation, 2001, 81, 317-326. | 3.7 | 17 |
| 124 | IL-6 Overexpression in ERG-Positive Prostate Cancer Is Mediated by Prostaglandin Receptor EP2. American Journal of Pathology, 2016, 186, 974-984. | 3.8 | 17 |
| 125 | MERTK as a novel therapeutic target in head and neck cancer. Oncotarget, 2016, 7, 32678-32694. | 1.8 | 17 |
| 126 | IL-4/5 signalling plays an important role during Litomosoides sigmodontis infection, influencing both immune system regulation and tissue pathology in the thoracic cavity. International Journal for Parasitology, 2017, 47, 951-960. | 3.1 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling. Oncotarget, 2017, 8, 7964-7976. | 1.8 | 16 |
| 128 | Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy. Oncology Letters, 2017, 13, 22-28. | 1.8 | 15 |
| 129 | Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 261-271. | 2.8 | 15 |
| 130 | GC1qR Cleavage by Caspase-1 Drives Aerobic Glycolysis in Tumor Cells. Frontiers in Oncology, 2020, 10, 575854. | 2.8 | 15 |
| 131 | Detection of TMPRSS2-ERG Fusion Gene Expression in Prostate Cancer Specimens by a Novel Assay Using Branched DNA. Urology, 2009, 74, 1156-1161. | 1.0 | 14 |
| 132 | Landscape of chromosome number changes in prostate cancer progression. World Journal of Urology, 2013, 31, 1489-1495. | 2.2 | 14 |
| 133 | Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression. Frontiers in Medicine, 2017, 4, 30. | 2.6 | 13 |
| 134 | The new ISUP 2014/WHO 2016 prostate cancer grade group system: first rÃ©sumÃ© 5Âyears after introduction and systemic review of the literature. World Journal of Urology, 2020, 38, 657-662. | 2.2 | 12 |
| 135 | ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 157-162. | 2.8 | 11 |
| 136 | Immunohistochemical assessment of lymphatic and blood vessel invasion in T1 urothelial carcinoma of the bladder. Scandinavian Journal of Urology, 2015, 49, 382-387. | 1.0 | 11 |
| 137 | Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma. Targeted Oncology, 2016, 11, 631-642. | 3.6 | 10 |
| 138 | Î±â€Methylacylâ€CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Followâ€up Study. Prostate, 2012, 72, 301-306. | 2.3 | 9 |
| 139 | Prognostic Significance and Functional Role of CEP57 in Prostate Cancer. Translational Oncology, 2015, 8, 487-496. | 3.7 | 9 |
| 140 | Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somaticTMPRSS2:ERGfusion status. Human Molecular Genetics, 2016, 25, ddw349. | 2.9 | 8 |
| 141 | Fountain of youth for squamous cell carcinomas? On the epigenetic age of nonâ€small cell lung cancer and corresponding tumorâ€free lung tissues. International Journal of Cancer, 2018, 143, 3061-3070. | 5.1 | 8 |
| 142 | Histomorphological analysis of false positive PI-RADS 4 and 5 lesions. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 636.e7-636.e12. | 1.6 | 7 |
| 143 | CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC. International Journal of Molecular Sciences, 2020, 21, 5508. | 4.1 | 6 |
| 144 | TRIM24 Expression as an Independent Biomarker for Prognosis and Tumor Recurrence in HNSCC. Journal of Personalized Medicine, 2022, 12, 991. | 2.5 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases. Carcinogenesis, 2021, 42, 1475-1484. | 2.8 | 5 |
| 146 | Inhibition of Cyclin-Dependent Kinase 8/Cyclin-Dependent Kinase 19 Suppresses ItsÂPro-Oncogenic Effects in Prostate Cancer. American Journal of Pathology, 2022, 192, 813-823. | 3.8 | 4 |
| 147 | Targeting cyclin-dependent kinase 7â€"association between CDK7 and pMED1 expression in prostate cancer tissue. Carcinogenesis, 2022, 43, 779-786. | 2.8 | 4 |
| 148 | CDK19 as a diagnostic marker for high-grade prostatic intraepithelial neoplasia. Human Pathology, 2021, 117, 60-67. | 2.0 | 3 |
| 149 | Up-regulation of POM121 is linked to prostate cancer aggressiveness and serves as a prognostic biomarker. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 380.e11-380.e18. | 1.6 | 1 |
| 150 | In silico analysis of anti-leukemia immune response and immune evasion in acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2493-2496. | 1.3 | 0 |